Logo for Stony Brook University
News and Media Relations header
  • Search Press Releases
Research News


School of Dental Medicine and Traverse Biosciences to Advance Emerging Treatment for Periodontal Disease
NIH Awards $1.3 million to the research partnership to evaluate a compound designed to reduce inflammation associated with the condition that affects millions worldwide


Dr. Lorne Golub, left, and Dr. Francis Johnson, inventors of the compounds to treat inflammation, manipulate the lead compound that will be evaluated by Traverse Biosciences. Also pictured are Joseph Scaduto of Traverse Biosciences and Dr. Maria Ryan of the School of Dental Medicine.

Stony Brook, NY, August 18, 2016 – The Stony Brook University School of Dental Medicine and Traverse Biosciences have received a $1.3 million award from the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) to further evaluate the pre-clinical safety and effectiveness of the Traverse Biosciences’ leading drug candidate, TRB-N0224, for the treatment of periodontal disease. The research will be led by Lorne Golub, DMD, in the Department of Oral Biology and Pathology, and Ying Gu, PhD, DDS, in the Department of General Dentistry at the School of Dental Medicine. They will serve as co-principle investigators of the award, in close collaboration with Traverse Biosciences.

Periodontal disease is one of the most prevalent diseases in the world, includes the major conditions of gingivitis and periodontitis, and is the primary cause of tooth loss in adults. The Centers for Disease Control (CDC) estimates that the prevalence of periodontitis in U.S. adults aged 30 years and older is 47.2% (64.7 million people). Periodontal disease has also been associated with other chronic conditions such as heart disease, diabetes, and various cancers. Periodontal disease also impacts companion animals, including dogs, cats and horses. Canine periodontal disease affects approximately 80% of dogs by the age of three, with the highest incidence in smaller breeds and older animals.


The research team evaluating compounds to potentially treat inflammatory diseases such are periodontitis assemble in their School of Dental Medicine laboratory. From left: Dr. Maria Ryan, Dr. Ying Gu, Dr. Lorne Golub, Joseph Scaduto, Dr. Francis Johnson, and Dr. Hsi-Ming Lee. In back, from left: Veena Raja and Jie Deng.

In 2015, Traverse Biosciences signed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York to develop a drug to treat canine periodontal disease. The leading drug candidate that has emerged and will be evaluated under the this NIDCR grant is derived from laboratory discoveries by Dr. Golub and Dr. Francis Johnson, President of Chem-Master International Inc., and Professor of Chemistry and Pharmacological Sciences at Stony brook University. They developed a library of drug candidates that are chemically-modified curcumins, which are designed to treat inflammation. The patents for the novel compounds list Drs. Golub and Johnson as the inventors. Traverse Biosciences will evaluate TRB-N0224 for the treatment of periodontal disease in both humans and animals.

“I am very pleased that Traverse Biosciences has been able to attract the financial resources necessary to advance this highly collaborative research and development program,” said Dr. Golub, SUNY Distinguished Professor and also a Scientific Co-Founder of Traverse Biosciences. “With this critical support from NIDCR, we can accelerate the commercialization of this platform technology for the treatment of periodontal disease, as well as a variety of other chronic inflammatory conditions.”

Joseph Scaduto, MS, MBA, Founder and CEO of Traverse Biosciences, stated, “We are working to successfully commercialize TRB-N0224 as an FDA-approved pharmaceutical intervention for the treatment of chronic inflammatory diseases in both humans and companion animals, including periodontal disease.”  He added, “This award from the National Institute of Dental and Craniofacial Research provides an infusion of non-dilutive capital that will allow us to demonstrate the pre-clinical safety and efficacy of this lead drug candidate.”

Dr. Gu, Associate Professor of Dentistry, commented, "I look forward to evaluating the therapeutic efficacy of TRB-N0224 to treat periodontal disease, and I am very pleased to work with Traverse Biosciences on this project. I strongly believe there is a need to develop new and improved therapeutics to manage chronic inflammatory diseases such as periodontitis. With this grant, we, as a team with Dr. Hsi-Ming Lee, a Research Assistant Professor in Oral Biology and Pathology, will be able to advance our research from bench top to chair side, from idea to commercialization." She added, "It is exciting to work closely with a new venture to develop a promising biomedical technology invented here at Stony Brook University"

Dr. Maria Ryan, a Co-Investigator on the award and Chair of the Department of Oral Biology and Pathology said, “The Department of Oral Biology and Pathology has been a prolific source of innovation throughout its history with numerous products successfully developed and commercialized. I am so proud to see this legacy continue with the invention of TRB-N0224 and our fruitful partnership with Traverse Biosciences.” 

Dr. Johnson, also a Scientific Co-Founder of Traverse Biosciences, stated, “TRB-N0224 represents an innovative therapeutic approach which focuses on resolving the chronic inflammation and tissue damage associated with periodontal disease that ultimately leads to bone and tooth loss.” He added, “Our experienced research team is very pleased to partner with Traverse Biosciences to commercialize this unique technology with broad applications in veterinary medicine and human health.”

The NIDCR award is defined as a Phase II Small Business Technology Transfer (STTR) grant.  Some of the STTR funding goes directly to the laboratory of Drs. Golub and Gu, and the work they and colleagues are doing evaluating the compounds in the School of Dental Medicine. The other portion of the funding goes to Traverse Bioscience for drug development and commercialization.


About the Stony Brook University School of Dental Medicine: The School of Dental Medicine at Stony Brook University was established in 1968 to define and shape the future as an international leader and innovator in dental education, patient care, research and service.  Its mission is to advance oral and general health throughout the local and global community, through the continuous pursuit of excellence in education, patient care, discovery and leadership. Since its inception, the School of Dental Medicine has achieved an enviable reputation for the excellence of its educational and research programs. To learn more about the School of Dental Medicine, visit http://dentistry.stonybrookmedicine.edu/.

About Traverse Biosciences: Traverse Biosciences is a privately-held emerging bioscience company launched to commercialize a proprietary pipeline of drug candidates to treat inflammatory diseases and age-related conditions affecting humans and companion animals. The company’s lead compound, TRB-N0224, is envisioned as the first FDA-approved, once-daily, edible prescription medication for the prevention of canine periodontal disease. For more information, Follow Traverse Biosciences on LinkedIn, or visit www.traversebiosciences.com.

Greg Filiano
Media Relations Manager, Stony Brook University School of Medicine
Office: 631.444.9343



© Stony Brook University